Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design
Open Access
- 1 September 2005
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (17) , 6233-6239
- https://doi.org/10.1158/1078-0432.ccr-05-0127
Abstract
Purpose: BMS-247550 is a semisynthetic derivative of epothilone B with mechanism of action analogous to paclitaxel. It has shown impressive antitumor activity in preclinical studies including in taxane-resistant models. We conducted a phase I trial, based on accelerated titration “2B” design, of BMS-247550 given as a 1-hour infusion every 3 weeks.Keywords
This publication has 12 references indexed in Scilit:
- A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group StudyJournal of Clinical Oncology, 2004
- A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancerAnnals of Oncology, 2004
- Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid TumorsClinical Cancer Research, 2004
- Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five DaysJournal of Clinical Oncology, 2003
- Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour InfusionsJournal of Clinical Oncology, 2002
- Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxelProceedings of the National Academy of Sciences, 1998
- Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone BProceedings of the National Academy of Sciences, 1998
- Accelerated Titration Designs for Phase I Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1997
- Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)Journal of Biological Chemistry, 1997
- Epothilons A and B: Antifungal and Cytotoxic Compounds from Sorangium cellulosum (Myxobacteria). Production, Physico-chemical and Biological Properties.The Journal of Antibiotics, 1996